ArticleFrontiers in oncology2025
Artificial intelligence-based evaluation of prognostic benefits from immunotherapy plus targeted therapy with or without radiotherapy or TACE in advanced hepatocellular carcinoma.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- CRAFITY and PALBI Define a Machine Learning-Supported Prognostic Framework in Hepatocellular Carcinoma-Data from an Eastern European Cohort with Low Macrotrabecular-Massive Prevalence.Diseases (Basel, Switzerland) · 2026Article
- Analysis of risk factors and prediction of prognosis in patients with primary liver cancer undergoing transarterial chemoembolization.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, and the prognosis of advanced disease is still poor. Immunotherapy plus targeted therapy has reshaped systemic treatment; however, the overall efficacy is limited. Increasing evidence suggests that combining systemic therapy with locoregional modalities such as transarterial chemoembolization (TACE) or radiotherapy (RT) may improve survival. Artificial intelligence (AI) offers the potential to refine prognostic prediction and optimize patient selection. Methods: We retrospectively analyzed 351 patients with unresectable HCC, classified into three groups: immunotherapy plus targeted therapy (P+T, Results: The median overall survival (mOS) was 12.8 months in the P+T group, 19.7 months in the TACE group ( Conclusion: Immunotherapy plus targeted therapy combined with TACE or RT significantly improved survival in advanced HCC compared with systemic therapy alone. RSF provided superior predictive performance and identified critical prognostic variables, supporting AI-assisted approaches as valuable tools for individualized risk stratification and treatment optimization in advanced HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.